Related by context. All words. (Click for frequent words.) 72 haematologic 71 non metastatic osteosarcoma 71 thalidomide Thalomid 70 relapsed MM 70 Fludarabine 69 Follicular Lymphoma 69 ara C 69 histologic subtype 69 SPRYCEL ® 69 metastatic malignant 68 hepatorenal syndrome 68 erlotinib Tarceva ® 68 refractory chronic lymphocytic 68 KRAS wild 68 TMP SMX 68 CHOP chemotherapy 68 small lymphocytic lymphoma 68 Peginterferon alfa 2b 68 CLL SLL 67 Pemetrexed 67 HBeAg negative 67 Retreatment 67 recurrent glioblastoma multiforme 67 grade cervical intraepithelial 67 Pegylated Interferon 67 colorectal liver metastases 67 basiliximab 67 urothelial carcinoma 67 metastatic renal cell carcinoma 67 juvenile idiopathic arthritis JIA 67 relapsed refractory multiple myeloma 67 mCRC patients 67 Folfox 67 CYT# potent vascular disrupting 67 Cloretazine 67 mRCC 67 lenalidomide Revlimid R 67 concurrent chemoradiation 66 leukemia CLL 66 recurrent NSCLC 66 Xelox 66 Toxicities 66 KRAS status 66 adalimumab Humira 66 standard chemotherapy regimen 66 Doxil ® 66 Diffuse Large B 66 acute leukemias 66 unfavorable cytogenetics 66 liposomal amphotericin B 66 subependymal giant cell 66 Flu Cy 66 infliximab Remicade 66 INCB# [003] 66 papillary renal cell carcinoma 66 Velcade bortezomib 66 canakinumab 66 Malignant Glioma 66 acute GvHD 66 metastatic lung cancer 66 lymphoid malignancies 66 TYGACIL 66 MALT lymphoma 66 sargramostim 66 alpha interferons 66 metastatic neuroendocrine tumors 66 Chronic Lymphocytic Leukemia CLL 66 pain palliation 66 squamous histology 66 tigecycline 66 ORENCIA R 66 Leukemias 66 cutaneous squamous cell carcinoma 66 KRAS mutations occur 66 Squamous 66 RoACTEMRA 66 galiximab 66 certolizumab 66 intravesical therapy 66 invasive candidiasis 66 calcineurin inhibitors 66 cisplatin gemcitabine 66 Evoltra ® 66 epithelial tumors 66 biliary tract cancer 66 corticosteroid therapy 66 Navelbine ® 66 FluCAM arm 66 metastatic GIST 66 atypical Hemolytic Uremic Syndrome 66 gefitinib Iressa 65 pegylated liposomal doxorubicin 65 superficial bladder cancer 65 recurrent metastatic 65 antiepileptics 65 hematologic toxicity 65 metastatic colorectal 65 leukemia AML 65 myelodysplastic myeloproliferative diseases 65 Hematologic 65 K ras mutations 65 cisplatin chemotherapy 65 hepatocellular carcinomas 65 bendamustine 65 gastrointestinal stromal tumors GIST 65 Soft Tissue Sarcoma 65 prostate carcinoma 65 dasatinib Sprycel 65 ALT flares 65 allogeneic HSCT 65 follicular NHL 65 multiple myeloma MM 65 trabectedin 65 Nilotinib 65 trastuzumab Herceptin ® 65 completely resected 65 candidemia 65 DMARDS 65 pegylated interferon alpha 65 Pharmacokinetics PK 65 caspofungin 65 macrolide antibiotic 65 grade gliomas 65 temsirolimus Torisel ® 65 β blockers 65 BARACLUDE ® 65 alefacept 65 BEXXAR Therapeutic Regimen 65 Chronic lymphocytic leukemia 65 CIMZIA ™ 65 invasive aspergillosis 65 abacavir Ziagen 65 Fludara 65 pediatric acute lymphoblastic 65 differentiated thyroid 65 tacrolimus ointment 65 de novo AML 65 CIMZIA TM certolizumab pegol 65 refractory AML 65 vWD 65 chronic lymphocytic leukemia CLL 65 pegylated interferon alfa 65 TORISEL 65 interferon ribavirin 65 HER2 overexpression 65 Sudhir Agrawal D.Phil 65 CTEPH 65 EGFR mutation positive 65 CANCIDAS 65 gastric adenocarcinoma 65 FOLFOX6 65 leucopenia 65 indolent NHL 65 elevated LDH 65 Lenalidomide 65 Helicobacter pylori eradication 65 Platinol ® cisplatin 65 lipid lowering agents 65 postoperative chemotherapy 65 mycophenolate mofetil 65 soft tissue sarcomas 65 hematopoietic cancers 65 HER2 positive metastatic breast 65 baseline LDH 65 refractory prostate cancer 64 ritonavir boosted 64 onset diabetes mellitus 64 adverse cytogenetics 64 MGd 64 CIN2 + 64 Dasatinib 64 AGILECT R 64 gemcitabine chemotherapy 64 hypereosinophilic syndrome 64 neutropaenia 64 sorafenib Nexavar 64 Decitabine 64 Raptiva ® 64 Erlotinib 64 hypomethylating agents 64 MabThera Rituxan 64 mycosis fungoides 64 SSc 64 alkylating agent 64 protease inhibitor PI 64 flutamide 64 HIV HCV coinfected 64 Temsirolimus 64 non squamous NSCLC 64 eribulin mesylate 64 neoplasias 64 Secondary Hyperparathyroidism 64 standard chemotherapy regimens 64 idarubicin 64 NOXAFIL 64 complement inhibitor eculizumab 64 Fludara ® 64 Platinol ® 64 stage IIIb IV 64 Hormone Refractory Prostate Cancer 64 intravenous bisphosphonates 64 anthracyclines taxanes 64 HSCT 64 Kit CD# positive 64 chemoradiation therapy 64 KRAS mutation 64 decitabine 64 ACTEMRA TM 64 Rilonacept 64 BEACOPP 64 hematologic parameters 64 surgically resectable 64 colorectal adenoma 64 Papillary 64 squamous cell carcinoma SCC 64 Myelodysplastic Syndrome MDS 64 Tarceva TM 64 DOXIL 64 systemic fungal infections 64 histological subtype 64 nonmetastatic 64 Gemzar ® 64 sorafenib tablets 64 Amrubicin 64 dacarbazine chemotherapy 64 HER2 positive cancers 64 evaluating tivozanib 64 systemic lupus erythematosus SLE 64 hyperphenylalaninemia HPA due 64 gemcitabine carboplatin 64 vinorelbine 64 ORENCIA ® 64 null responder 64 chronic HBV 64 eosinophilic asthma 64 Leukine ® 64 aspirin clopidogrel 64 metastatic RCC 64 systemic corticosteroid 64 ritonavir boosted protease inhibitor 64 acute myeloid 64 pegylated interferons 64 basal cell carcinoma BCC 64 antiarrhythmic drug 64 histologies 64 NAVISTAR R 64 deep venous thromboses 64 trials RCTs 64 heavily pretreated 64 T2DM 64 MAGE A3 ASCI 64 gastrointestinal stromal tumor GIST 64 malignant neoplasms 64 biologic DMARD 64 Glioblastoma Multiforme 64 concomitant medications 64 MDS AML 64 transaminase elevations 64 nonalcoholic steatohepatitis NASH 64 squamous cell lung cancer 64 GISTs 64 amoxicillin clavulanate 64 primary hypercholesterolemia 64 skeletal metastases 64 metastatic CRC 64 ovarian carcinoma 64 myelodysplastic syndrome MDS 64 grade cervical dysplasia 64 pancreatic adenocarcinoma 64 visilizumab 64 Naive Patients 64 aripiprazole Abilify 64 docetaxel Taxotere 64 retinal vein occlusion 64 quetiapine Seroquel 64 Combination therapy 64 recombinant interferon 64 anthracycline containing 64 hepatocellular cancer 64 imatinib resistant 64 liposomal doxorubicin 64 micafungin 64 antithrombotics 64 conventional DMARDs 64 elevated ALT 64 insulin glulisine 64 NovoTTF 64 Capecitabine 64 NMDA antagonists 64 nonsmall cell lung cancer 64 nonnucleoside reverse transcriptase inhibitors 64 AA Amyloidosis 64 leukotriene receptor antagonist 64 Golimumab 63 oral Hycamtin 63 hepatic cirrhosis 63 calcineurin inhibitor 63 concomitant AEDs 63 TEAEs 63 FOLFIRI alone 63 ceftazidime 63 cytotoxic chemotherapy 63 metastatic bladder 63 chronic idiopathic thrombocytopenic purpura 63 Gleevec resistant 63 anemia neutropenia 63 lenalidomide dexamethasone 63 receptor tyrosine kinase inhibitor 63 Gleevec imatinib mesylate 63 Genentech Rituxan 63 cancer mCRC 63 GnRH agonists 63 Hodgkin lymphoma HL 63 infusional 5-FU/LV 63 Cutaneous T 63 ELOXATIN 63 resectable 63 juvenile idiopathic arthritis 63 refractory indolent non 63 TEMODAL 63 Xanafide 63 peripheral sensory neuropathy 63 forodesine 63 hematologic abnormalities 63 abacavir lamivudine 63 FOLFIRI 63 BENICAR HCT 63 aldosterone antagonist 63 osteosarcomas 63 polyarticular 63 Leucovorin 63 AVONEX ® 63 Patients Treated With 63 fosamprenavir 63 melphalan prednisone 63 Hepatocellular Carcinoma HCC 63 bortezomib Velcade 63 lumiliximab 63 dexamethasone Decadron 63 EGFR tyrosine kinase inhibitors 63 Tasigna nilotinib 63 overactive bladder syndrome 63 NMIBC 63 HeFH 63 unresectable 63 metastatic malignant melanoma 63 pancreatic enzyme replacement 63 assessing T DM1 63 endocrine therapies 63 pertuzumab 63 trans retinoic acid 63 Vaprisol 63 glioblastoma multiforme GBM 63 erlotinib Tarceva 63 cutaneous melanoma 63 BR.# 63 Tumor Response 63 Adjuvant chemotherapy 63 Pegasys ® 63 cinacalcet 63 advanced hepatocellular carcinoma 63 severe hypersensitivity reactions 63 cell lymphoma CTCL 63 autoantibody positive 63 glatiramer acetate 63 Relapsed Refractory 63 nosocomial pneumonia 63 CAELYX 63 Infusion Reactions Severe 63 INVANZ 63 immunosuppressive therapies 63 Vidaza ® 63 atypical hemolytic uremic syndrome 63 dasatinib 63 mycophenolate 63 Oxaliplatin 63 hypercholesterolaemia 63 cutaneous T 63 ARCALYST ® 63 latent tuberculosis infection 63 rilonacept 63 Relapsing Remitting Multiple Sclerosis 63 coinfected patients 63 mCRPC 63 Paraplatin ® 63 amphotericin B 63 Interferon alfa 63 MYCAMINE 63 neuroendocrine cancers 63 decompensated liver disease 63 ß blockers 63 Haptoglobin 63 Adjunctive 63 anti angiogenic agents 63 Ozarelix 63 Fondaparinux 63 ANCA associated 63 SCCHN 63 HoFH 63 APTIVUS r 63 CIN3 63 antiemetics 63 imatinib Gleevec ® 63 refractory cutaneous T 63 metastatic gastric 63 myopathy rhabdomyolysis 63 posaconazole 63 etanercept Enbrel 63 Omacetaxine 63 symptomatic BPH 63 Sutent sunitinib 63 Investigational Treatment 63 tolterodine ER 63 tricyclic antidepressant 63 biologic therapy 63 NATRECOR R 63 Vidaza azacitidine 63 carcinoid tumors 63 dose cytarabine 63 docetaxel Taxotere ® 63 Gastrointestinal Stromal Tumors 63 diabetic kidney 63 estramustine 63 PEGINTRON TM 63 daunorubicin 63 Nexavar sorafenib 63 trastuzumab Herceptin R 63 miconazole Lauriad ® 63 AVASTIN 63 CTAP# Capsules 63 tumor histology 63 lenalidomide Revlimid 63 toenail onychomycosis 63 Lymphocytic 63 relapsed ALL 63 dasatinib Sprycel ® 63 BCG refractory 63 Triapine 63 cervical intraepithelial neoplasia 63 cIAI 63 pegylated alpha interferon 63 bevacizumab Avastin ® 63 antiangiogenic agent 63 xanthine oxidase inhibitor 63 Interferon Beta 63 monoclonal anti 63 topical calcineurin inhibitors 63 HBeAg negative patients 63 gadobutrol 63 Epratuzumab 63 Bevacizumab 63 neutropenic 63 PROCRIT ® 63 nephrotoxicity 63 PD LID 63 tipranavir ritonavir 63 Gorlin syndrome 63 lymphocytic leukemia 63 placebo dexamethasone 63 receiving highly emetogenic 63 constipation OIC 63 peritumoral brain edema 63 clinically evaluable 63 ethambutol 63 Targretin capsules 63 bladder carcinoma 63 cutaneous T cell 63 investigational monoclonal antibody 63 myelofibrosis polycythemia vera 63 TNF alpha antagonist 63 Mantle Cell Lymphoma 63 Juvenile Idiopathic Arthritis 63 systemic ALCL 63 salmeterol fluticasone propionate 63 Exelixis XL# 63 Prolongs Survival 63 platinum refractory 63 unresectable tumors 63 bronchogenic carcinoma 63 relapsing remitting MS RRMS 62 vinca alkaloid 62 phase IIb trial 62 Refractory Hodgkin Lymphoma 62 malignant neoplasm 62 lupus nephritis 62 gastric carcinoma 62 deletion 5q 62 tumor subtypes 62 demonstrated antitumor activity 62 macrolide antibiotics 62 microtubule inhibitor 62 pediatric Crohn disease 62 Enzastaurin 62 malignant pleural mesothelioma 62 Systemic Lupus Erythematosus SLE 62 receiving Vectibix monotherapy 62 selective modulator 62 TNF antagonist 62 ® lenalidomide 62 temsirolimus 62 endometrial hyperplasia 62 Pafuramidine 62 hepatic encephalopathy HE 62 PsA 62 lymphoma subtypes 62 oropharyngeal candidiasis OPC 62 thromboembolic disease 62 Degarelix 62 chronic immune thrombocytopenic 62 non resectable metastatic 62 IBS C 62 Efficacy Trial 62 squamous 62 Cimzia TM 62 chronic hemodialysis 62 cranial irradiation 62 Irinotecan 62 Idiopathic Pulmonary Fibrosis 62 anthracycline taxane 62 darunavir r 62 Pertuzumab 62 Tasimelteon 62 PASI scores 62 hepatitis C genotype 62 ABSSSI 62 gastrointestinal stromal tumors GISTs 62 nonalcoholic steatohepatitis 62 macroalbuminuria 62 hematological disorders 62 Ranolazine 62 systemic anaplastic large 62 CIMZIA TM 62 Sanofi Aventis Taxotere 62 imatinib therapy 62 pegfilgrastim 62 non Hodgkin lymphomas 62 non squamous histology 62 aromatase inhibitors AIs 62 Patients Receiving 62 Glioblastoma Multiforme GBM 62 Hsp# Inhibitor 62 Thrombocytopenia 62 chronic periodontitis 62 Myelodysplastic Syndromes 62 Neulasta ® 62 dopaminergic therapy 62 TORISEL TM 62 medically inoperable 62 adriamycin 62 symptomatic carotid stenosis 62 smoldering multiple myeloma 62 APTIVUS 62 mTOR inhibitor 62 adrenocortical cancer 62 Cardiotoxicity 62 Acute Myeloid Leukemia 62 HNSCC 62 kidney urologic 62 serologically active systemic lupus 62 FOLFOX regimen 62 NEUPOGEN 62 5-FU/LV 62 esophageal candidiasis 62 aldosterone antagonists 62 doxorubicin Adriamycin 62 VELCADE melphalan 62 endothelin receptor antagonists 62 recurrent glioblastoma 62 Clolar ® 62 efavirenz EFV 62 histologically confirmed 62 ZYVOX 62 tyrosine kinase inhibitor TKI 62 induced anemia 62 inhaled bronchodilators 62 nitrofurantoin 62 imipenem 62 Lupus Nephritis 62 chemotherapeutic regimen 62 gemcitabine Gemzar 62 autologous SCT 62 HGPIN 62 BEXXAR 62 mutated K ras 62 FluCAM 62 Sprycel dasatinib 62 Crohn disease CD 62 leukemia ALL 62 rALLy 62 Intravitreal injections 62 chemoradiation 62 sorafenib Nexavar ® 62 Tigecycline 62 nonmelanoma skin cancers 62 preoperative chemotherapy 62 QTc prolongation 62 Surgical resection 62 myeloproliferative neoplasms 62 mitochondrial toxicity 62 Hodgkin lymphoma NHL 62 Tamibarotene 62 duplex ultrasonography 62 T1c 62 advanced metastatic prostate 62 relapsed SCLC 62 antiangiogenic therapy 62 Non inferiority 62 demethylation agents 62 thymoma 62 Aryplase 62 pemphigus vulgaris 62 antimuscarinic 62 ACE Inhibitors 62 Metastatic Prostate Cancer 62 pan HDAC inhibitor 62 metastatic renal cell 62 liver metastasis 62 astrocytomas 62 Cytarabine 62 STRIDE PD 62 unresectable stage 62 Bayer HealthCare Onyx Pharmaceuticals 62 AGHD 62 polyp recurrence 62 Eltrombopag 62 proctitis 62 Alemtuzumab 62 Rheumatoid Arthritis Patients 62 prednisone prednisolone 62 elevated serum creatinine 62 sunitinib Sutent 62 HER2 expression 62 thrombocytopenic 62 novel VDA molecule 62 paclitaxel Taxol 62 Mitomycin C 62 mutated KRAS gene 62 olmesartan 62 tipranavir r 62 heterozygous FH 62 acute promyelocytic leukemia APL 62 efalizumab 62 BCR ABL inhibitor 62 GH deficiency 62 pancreatic insufficiency 62 prognostic variables 62 pT2 62 docetaxel chemotherapy 62 interferon alfa 2b 62 seropositive patients 62 cetuximab Erbitux ® 62 ER CHOP 62 plus gemcitabine 62 refractory acute myeloid 62 sipuleucel T 62 Phase #/#a trial 62 Revlimid lenalidomide 62 posterior uveitis 62 hormone receptor negative 62 cholangiocarcinoma 62 Clofarabine 62 tenofovir emtricitabine 62 haematological 62 cilengitide 62 chronic HBV infection 62 rituximab Rituxan 62 T1DM 62 hypercalcemia 62 pharmacokinetic interactions 62 multimodality therapy 62 Bendamustine 62 FASLODEX 62 oxycodone CR 62 pulmonary hypertension PH 62 FOR FURTHER INFORMATION ABOUT 62 antiandrogen 62 pancreatic prostate 62 mapatumumab 62 p# biomarker 62 G CSFs 62 potentially hepatotoxic 62 Teriflunomide 62 budesonide foam 62 gastrointestinal stromal tumor 62 antiretroviral naïve 62 paclitaxel cisplatin 62 CsA 62 cisplatin resistant 62 tuberous sclerosis TS 62 Abatacept 62 malignant ascites 62 bronchial hyperresponsiveness 62 Noxafil 62 castrate resistant prostate cancer 62 interferon gamma 1b 62 Taxotere ® 62 Elagolix 62 neutropenia thrombocytopenia 62 imatinib resistance 62 FOLFOX chemotherapy 62 factor TNF 62 AGILECT ® 62 rosuvastatin #mg 62 AZT zidovudine Retrovir 62 colorectal cancer CRC 62 Adenomas 62 Aflibercept 62 immunocompetent patients 62 tyrosine kinase inhibitors TKIs 62 Darinaparsin 62 unresectable HCC 62 recurrent glioblastoma multiforme GBM 62 doxorubicin docetaxel 62 OvaRex ® MAb 62 smoldering myeloma 62 vismodegib 62 Fulvestrant 62 mitoxantrone plus 62 hepatic insufficiency 62 STELARA ™ 62 SJIA 62 PhG alpha 1 62 Brentuximab Vedotin SGN 62 Mitoxantrone 62 6 mercaptopurine 62 anagrelide 62 chemotherapy induced neutropenia 62 azacitidine 62 familial amyloidotic polyneuropathy FAP 62 ZOLINZA 62 Renal Cell Carcinoma 62 acitretin 62 cediranib 62 renal cell carcinomas 62 fluoropyrimidine 62 gemifloxacin 62 ritonavir boosted lopinavir 62 esophagitis 62 elotuzumab 62 PSA nadir 62 venous thromboembolic events 62 voriconazole 62 topically administered 61 PKC# 61 Etanercept 61 Mg Usa 61 nicardipine 61 anastrazole 61 denileukin diftitox 61 NOMID 61 Peginterferon Alfa 2a 61 Glucocorticoids 61 basal cell nevus syndrome 61 achieved ACR# 61 peginterferon alfa 61 myeloproliferative diseases 61 Aplidin 61 ADPKD 61 curative resection 61 alkylating agents 61 overt nephropathy 61 rFVIIa 61 Cell Lymphoma 61 oral antidiabetic medication 61 pentoxifylline 61 ixabepilone 61 polycythemia vera PV 61 cytotoxic therapies 61 monoinfected patients 61 Severe Sepsis 61 stage IIIB 61 enterococcal 61 fluvastatin 61 Tyrosine Kinase Inhibitors 61 FOLPI 61 Interferon beta 1a 61 Arranon 61 trimethoprim sulfamethoxazole 61 follicular lymphomas 61 lymphoproliferative disorders 61 AEG# 61 nilotinib 61 hematologic disorders 61 hepatic metastases 61 serum HBV DNA 61 locoregional 61 cidofovir 61 cranial radiation 61 AST ALT 61 chronic GVHD 61 Virologic 61 atypical ductal hyperplasia 61 azacytidine 61 discontinued Viread 61 malignant lymphomas 61 HDAC Inhibitor 61 5 Fluorouracil 61 steroid dexamethasone 61 tocilizumab 61 thromboembolic events 61 nucleoside analogues 61 refractory chronic myeloid 61 #F FDG PET 61 Torisel 61 nodal metastasis 61 Dapagliflozin 61 prostate cancer PCa 61 6R BH4 61 Febrile neutropenia 61 benign neoplasms 61 Peginterferon 61 uric acid lowering 61 Metastatic Colorectal Cancer 61 chronic eosinophilic leukemia 61 recurrent malignant glioma 61 adenocarcinomas 61 anemias 61 refractory CLL 61 clinicopathological features 61 erythema nodosum 61 piperacillin tazobactam 61 leukaemias 61 SNT MC# 61 Myelosuppression 61 refractory NSCLC 61 diabetes mellitus DM 61 Anthracycline 61 paricalcitol 61 5 fluorouracil leucovorin 61 Castration Resistant Prostate Cancer 61 moderate renal impairment 61 metastatic castration resistant 61 TNF blocker therapy 61 gp# vaccine 61 chlorambucil 61 mg BID dose 61 febrile neutropenia 61 low dose cytarabine 61 proteasome inhibitor 61 VAPRISOL 61 previously untreated follicular 61 bevacizumab Avastin 61 Corticosteroids 61 grade glioma 61 lung cancer NSCLC 61 mCRC 61 quinolone 61 malignant lymphoma 61 Immunohistochemical staining 61 arterial thrombosis 61 haematologic malignancies 61 CBLC# 61 paclitaxel carboplatin 61 methotrexate therapy 61 genotypic resistance 61 Free Survival PFS 61 renal impairment 61 Hurthle cell 61 International Prognostic Scoring 61 Kinoid 61 antithrombotic agents 61 Tarceva erlotinib 61 echinocandin 61 XIENCE V PROMUS Stent 61 IMiDs ® compound 61 immunocompetent 61 octreotide LAR 61 mycophenolate mofetil MMF 61 KETEK 61 imatinib Gleevec 61 psoriatic arthritis PsA 61 overlapping toxicities 61 methotrexate monotherapy 61 Chronic Myeloid Leukemia 61 metaglidasen 61 Gefitinib 61 Lambert Eaton Myasthenic 61 cytoreduction 61 MCyR 61 Pivotal Study 61 Cytotoxic 61 atazanavir ritonavir 61 cyclophosphamide Cytoxan 61 Nesiritide 61 EXJADE 61 relapsed leukemia 61 therapeutic regimens 61 refractory Hodgkin 61 viral kinetics 61 androgen ablation 61 fibromyalgia syndrome 61 riociguat 61 pamidronate 61 doxorubicin cyclophosphamide 61 Chronic Heart Failure 61 ARCOXIA 61 Genasense ® 61 vincristine doxorubicin 61 BRIM2 61 CP CPPS 61 sleeve lobectomy 61 phase IIb study 61 Lamotrigine 61 risperidone Risperdal 61 ribavirin RBV 61 prophylactic cranial irradiation 61 fludarabine cyclophosphamide 61 secondary hyperparathyroidism 61 patients receiving myelosuppressive 61 symptomatic hyponatremia 61 relapsed multiple myeloma 61 Advanced Renal Cell 61 acyclovir Lauriad R 61 intracranial hemorrhage ICH 61 EOquin 61 Known hypersensitivity 61 dose dexamethasone 61 Cholinesterase Inhibitors 61 MabCampath 61 romiplostim 61 oblimersen 61 Daptomycin 61 ZACTIMA 61 prospectively enrolled 61 Adjuvant Treatment 61 YONDELIS 61 colorectal lung 61 antibiotic regimens 61 mycophenolic acid 61 pomalidomide 61 paliperidone ER 61 Alequel 61 Complicated Skin 61 Gleevec Glivec 61 APTIVUS R 61 Bortezomib 61 Newly Diagnosed Multiple Myeloma 61 metastatic renal 61 Advanced Melanoma 61 radiochemotherapy 61 boosted protease inhibitor 61 torsade de pointes 61 gallium nitrate 61 breast cancer subtypes 61 CellCept mycophenolate mofetil 61 nasopharyngeal carcinoma 61 adjuvant cisplatin 61 refractory metastatic colorectal cancer 61 acarbose 61 immunosuppressive regimen 61 Ceflatonin 61 chronic myeloid 61 taxane refractory 61 Ibritumomab Tiuxetan 61 BENICAR 61 infective endocarditis 61 follicular lymphoma 61 Pegintron 61 Azacitidine 61 tamoxifen Nolvadex ® 61 SHPT 61 acetonide FA 61 abiraterone acetate 61 Acute Myeloid Leukemia AML 61 Pivotal Phase III 61 fosbretabulin 61 Monotherapy 61 eosinophilic pneumonia 61 CTAP# 61 cardiotoxic 61 gemcitabine Gemzar ® 61 T#I [002] 61 taxane chemotherapy 61 Ceftaroline 61 complete cytogenetic response 61 risperidone olanzapine 61 Ceplene/IL-2 61 cirrhosis liver failure 61 Sezary syndrome 61 anthracycline chemotherapy 61 BRAF mutations 61 receiving VELCADE 61 epoetin alpha 61 BCR ABL mutations 61 treat chronic sinusitis 61 herpetic keratitis 61 COPAXONE R 61 azilsartan medoxomil 61 immunosuppressive agents 61 ARB telmisartan 61 metastatic kidney 61 KRAS mutant tumors 61 nucleoside analogs 61 sertraline Zoloft 61 poor metabolizers 61 pyrazinamide 61 superficial basal cell carcinoma 61 FUSILEV enhances 61 dosing cohort